...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature cancer. >Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
【24h】

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

机译：适应性免疫和中和抗体针对SARS-CoV-2变异的担忧在癌症患者免疫接种:捕捉研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable titers of neutralizing antibodies (NAbT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) versus wild-type (WT) SARS-CoV-2. Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid cancers against both SARS-CoV-2 WT and VOC. By comparison with individuals without cancer, patients with hematological, but not solid, malignancies had reduced neutralizing antibody (NAb) responses. Seroconversion showed poor concordance with NAbT against VOC. Previous SARS-CoV-2 infection boosted the NAb response including against VOC, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T cell responses were detected in 80% of patients and were comparable between vaccines or cancer types. Our results have implications for the management of patients with cancer during the ongoing COVID-19 pandemic.
机译：冠状病毒疾病2019 (COVID-19)抗病毒反应在pan-tumor免疫监视(捕捉)(NCT03226886)是一个前瞻性群组研究COVID-19患者免疫力癌症。两个剂量的BNT162b2或管理工作AZD1222疫苗,接种12周。两剂分别为85%和后血清转化速率59%的患者的固体和血液分别为恶性肿瘤。患者检测到中和滴度对严重急性抗体(NAbT)呼吸系统综合症冠状病毒2 (SARS-CoV-2)变异的担忧(VOC)与野生型(WT)SARS-CoV-2。恶性肿瘤的可能性更大检测不到NAbT NAbT中值低于那些有固体癌症SARS-CoV-2WT和挥发性有机化合物。没有癌症,患者血液,但是不稳固,恶性肿瘤减少中和抗体(NAb)反应。贫穷对VOC NAbT一致。SARS-CoV-2感染了NAb响应包括对VOC和anti-CD20治疗NAbT与被探测。诱发T细胞反应中发现80%的病人之间的可比性疫苗或癌症类型。对患者的管理癌症的COVID-19大流行期间。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号